Fast Track Designation for Chronic Heart Failure Drug Ivabradine

Fast Track Designation for Chronic Heart Failure Drug Ivabradine

Ivabradine, also known as the brand name drug Procorlan which is marketed by Servier, recently received a fast track from the FDA for the treatment of chronic heart failure. As an efficacious drug which inhibits the IF current in the sinoatrial node, Ivabradine has proven to be a virtuous symptomatic treatment for chronic stable angina pectoris. Many patients with chronic heart failure who also have a normal sinus rhythm are unfortunately intolerant to the current best in care treatment of beta-blockers. The advent of investigational Ivabradine and the current fast-track status from the FDA offers a much needed treatment option for the 5.1 million patients in the United States suffering from this debilitating condition. There are 27 countries who have received marketing authorizations for Procorlan {Ivabradine} from the European Medicines Evaluation Agency.

Ivabradine CAS 155974-00-8

A typical starting dose of Ivabradine is 5 milligrams, taken twice daily. Patients are usually titrated up in their dose to 7.5 milligrams, to be taken twice a day. Ivabradine is currently available as film coated tablets in both 5 milligram and 7.5 milligram doses. The unique ability of Ivabradine to act as a selective inhibitor of the cardiac pacemaker and work as an agent to lower heart rate, without significant adverse effects, is extremely encouraging. Current treatments for the majority of patients with chronic heat failure include the administration of beta-blockers; this class of drugs often lead to undesirable side effects, such as brachycardia, constriction of the airways and rebound phenomena. Additionally, as heat rate reduction is so important for patients who have chronic heart failure with angina, beta blockers often fail to provide adequate relief for rapid heart rate. However, Ivabradine provides a convincing dose-dependent reduction in the patient’s heart rate, which leads to a subsequent reduction in the rate pressure and in myocardial oxygen consumption.

A sizable study involving roughly 5,000 patients with chronic heart failure showed impressive and compelling results. When compared to the beta-blocker Atenolol and the calcium channel blocker Amlodipine, participants who were dosed with Ivabradine reported a significant decrease in their angina attacks. An overall sustained reduction in heart rate was observed in patients who were treated with Ivabradine for at least one full year, and this patient group reported no adverse effects. An astounding 26 million people worldwide endure a life with chronic heart failure, and this number is only predicted to rise. Cases of chronic heart failure are projected by the World Health Organization to grow by 25 percent by the year 2030. Research and development for new and effectual treatments are urgently needed.

LGM Pharma provides Ivabradine CAS# 155974-00-8 and Ivabradine Hydrochloride CAS# 148849-67-6 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.


  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service